|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, the role of microRNA-765/EZH1 axis in the progression of BCa was assessed.
|
31396353 |
2019 |
|
leukemia
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia.
|
31699991 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our analysis implicated <i>BCL2</i> expression level as an important indicator of venetoclax responsiveness and provided a rationale for its targeting in specific leukemia subtypes and multiple myeloma, linked several polycomb group proteins that could be targeted by small molecules (SFMBT1, CBX7, and EZH1) with chronic lymphocytic leukemia, and supported <i>CDK6</i> as a disease-specific target in acute myeloid leukemia.
|
30940663 |
2019 |
|
Fibrosis, Liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
Loss of Ezh1 and Ezh2 also resulted in liver fibrosis.
|
30689973 |
2019 |
|
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.010 |
Biomarker
|
disease |
BEFREE |
Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57<sup>CDKN1C</sup> and TP53INP1 in mantle cell lymphoma.
|
31565482 |
2019 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, the role of microRNA-765/EZH1 axis in the progression of BCa was assessed.
|
31396353 |
2019 |
|
Malignant Peripheral Nerve Sheath Tumor
|
0.010 |
Biomarker
|
disease |
BEFREE |
Instead, we show that EZH1 and EZH2 are functionally redundant in the slowly proliferating MPNST precursors.
|
30867289 |
2019 |
|
Childhood Leukemia
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia.
|
31699991 |
2019 |
|
Oncovirus infection
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Inactivation of chromatin-associated genes (ARID1A, SMARCA4/BRG1, SMARCB1/SNF5, KDM6A/UTX, BAP1, KMT2D/MLL2) and oncovirus infection (HTLV-1, EBV) trigger EZH1/2 perturbation and H3K27me3 deposition.
|
31747604 |
2019 |
|
Mantle cell lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57<sup>CDKN1C</sup> and TP53INP1 in mantle cell lymphoma.
|
31565482 |
2019 |
|
Schizophrenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
EZH1 is dysregulated in schizophrenia, sensitive to antipsychotic medications, and a brain-enriched miR-132 target that controls neurobehavioral phenotypes.
|
30099093 |
2018 |
|
Thyroid Neoplasm
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Thyroid tumors with EZH1 mutations reported in the literature were benign in most cases.
|
29723601 |
2018 |
|
Adenocarcinoma, Oxyphilic
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
EZH1 mutations were detected in 3% of follicular adenoma and in 20% of Hürthle cell adenoma, and one minimally invasive Hürthle cell carcinoma.
|
29723601 |
2018 |
|
Follicular adenoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
EZH1 mutations were detected in 3% of follicular adenoma and in 20% of Hürthle cell adenoma, and one minimally invasive Hürthle cell carcinoma.
|
29723601 |
2018 |
|
Hematologic Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Histone methyltransferases enhancer of zeste homolog 1 and 2 (EZH1/2), which are subunits of polycomb repressive complexes (PRC), are recurrently mutated or highly expressed in many hematological malignancies.
|
29845708 |
2018 |
|
Hurthle Cell Tumor
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
EZH1 mutations were detected in 3% of follicular adenoma and in 20% of Hürthle cell adenoma, and one minimally invasive Hürthle cell carcinoma.
|
29723601 |
2018 |
|
Thyroid Gland Oncocytic Adenoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
EZH1 mutations were detected in 3% of follicular adenoma and in 20% of Hürthle cell adenoma, and one minimally invasive Hürthle cell carcinoma.
|
29723601 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results indicate that miR-17-5p down-regulation contributes to erlotinib resistance of NSCLC by modulating its target genes such as EZH1 and plasma miR-17-5p might be a potential biomarker of erlotinib response in NSCLC patients.
|
27633093 |
2017 |
|
Glioma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Survival analysis then revealed a five-PcG gene signature one protective gene (enhancer of zeste homolog 1) and four risky genes (EZH2, PHD finger protein 19, DNMT3A and DNMT3B), which may identify patients with high risk of poor prognosis of glioma.
|
28454437 |
2017 |
|
Huntington Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
H3K9me3-specific ChIP-on-ChIP analysis identified that the H3K9me3-enriched epigenome signatures of multiple neuronal pathways including Egr1, Fos, Ezh1, and Arc are deregulated in HD transgenic (R6/2) mice.
|
28593442 |
2017 |
|
Nodule
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Somatic mutation of BRAF (22/32) is only detected in PTC, while mutations in SPOP (4/38), ZNF148 (6/38) and EZH1 (3/38) are found enriched in adenomatoid nodule.
|
28580939 |
2017 |
|
Small cell carcinoma of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Mechanistic investigations showed that HOTTIP functions as an oncogene in SCLC progression by sponging miR-574-5p and affecting the expression of polycomb group protein EZH1.
|
29041935 |
2017 |
|
Papillary thyroid carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Somatic mutation of BRAF (22/32) is only detected in PTC, while mutations in SPOP (4/38), ZNF148 (6/38) and EZH1 (3/38) are found enriched in adenomatoid nodule.
|
28580939 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, targeting EZH1 could be therapeutically useful in ccRCC.
|
28701475 |
2017 |
|
Malignant neoplasm of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the preclinical effects of UNC1999, a dual inhibitor of EZH2 and EZH1, in combination with proteasome inhibitors on multiple myeloma and prostate cancer.<b>Experimental Design:</b><i>In vitro</i> and <i>in vivo</i> efficacy of UNC1999 and the combination with proteasome inhibitors was evaluated in multiple myeloma cell lines, primary patient cells, and in a xenograft model.
|
28490465 |
2017 |